Targeting the extracellular signal-regulated kinase 1 (ERK1; encoded by MAPK3) and ERK2 (ERK2; encoded by MAPK1) may suppress diverse protumorigenic cellular phenotypes such as carcinogenesis, proliferation, angiogenesis, survival, metastasis, migration, invasion, and epithelial-to-mesenchymal transition (EMT) of PC cells and further alleviate resistance to anoikis and chemotherapeutics [90–95]. This evidence concerns the gene MAPK3 and pachyonychia congenita.